Suramin: Rapid loading and weekly maintenance regimens for cancer patients

R. E N Van Rijswijk, A. C. Van Loenen, J. Wagstaff, E. Meijer, R. Lopez, C. J. Van Groeningen, J. J. Heimans, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

Purpose: Suramin is an anticancer agent with a narrow therapeutic window and a terminal half-life of 45 to 55 days. These characteristics make it necessary to control accurately the serum concentrations of the drug. Therefore, the aim of the present study was to develop a rapid loading regimen, followed by weekly administration of suramin to maintain serum concentrations of between 150 and 300 μg/mL for 8 weeks. Patients and Methods: Eligible patients were treated with five different loading regimens. Initially, weekly maintenance doses were estimated manually by the treating physician. Subsequently, computer-assisted dosing that used Bayesian pharmacokinetic modeling was used. Results: Thirty-eight courses of suramin that were administered to 35 patients were studied. The optimal loading regimen consisted of a continuous infusion of 600 mg/m2 during a 24-hour period, which resulted in a mean serum concentration of 319 μg/mL. Potentially toxic concentrations that were observed with shorter infusions were avoided. Maintenance treatment, which used the weekly administration of suramin during a 6-hour period, seemed to be able to maintain mean suramin serum trough concentrations of 150 μg/mL, while preventing mean peak concentrations of more than 300 μg/mL. The use of Bayesian pharmacokinetics was superior to manual estimation in tailoring the optimal dose to the therapeutic window. Conclusions: Continuous infusion is the optimal way of delivering suramin during the loading phase. To maintain trough levels and peak levels within a narrower therapeutic window, suramin will have to be administered more frequently than once a week. Bayesian modeling based on individual serum levels and population pharmacokinetics allows accurate dosing to maintain suramin levels within the therapeutic window.

Original languageEnglish (US)
Pages (from-to)1788-1794
Number of pages7
JournalJournal of Clinical Oncology
Volume10
Issue number11
StatePublished - 1992
Externally publishedYes

Fingerprint

Suramin
Maintenance
Neoplasms
Serum
Pharmacokinetics
Therapeutics
Poisons
Antineoplastic Agents
Half-Life
Physicians

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Van Rijswijk, R. E. N., Van Loenen, A. C., Wagstaff, J., Meijer, E., Lopez, R., Van Groeningen, C. J., ... Pinedo, H. M. (1992). Suramin: Rapid loading and weekly maintenance regimens for cancer patients. Journal of Clinical Oncology, 10(11), 1788-1794.

Suramin : Rapid loading and weekly maintenance regimens for cancer patients. / Van Rijswijk, R. E N; Van Loenen, A. C.; Wagstaff, J.; Meijer, E.; Lopez, R.; Van Groeningen, C. J.; Heimans, J. J.; Pinedo, H. M.

In: Journal of Clinical Oncology, Vol. 10, No. 11, 1992, p. 1788-1794.

Research output: Contribution to journalArticle

Van Rijswijk, REN, Van Loenen, AC, Wagstaff, J, Meijer, E, Lopez, R, Van Groeningen, CJ, Heimans, JJ & Pinedo, HM 1992, 'Suramin: Rapid loading and weekly maintenance regimens for cancer patients', Journal of Clinical Oncology, vol. 10, no. 11, pp. 1788-1794.
Van Rijswijk REN, Van Loenen AC, Wagstaff J, Meijer E, Lopez R, Van Groeningen CJ et al. Suramin: Rapid loading and weekly maintenance regimens for cancer patients. Journal of Clinical Oncology. 1992;10(11):1788-1794.
Van Rijswijk, R. E N ; Van Loenen, A. C. ; Wagstaff, J. ; Meijer, E. ; Lopez, R. ; Van Groeningen, C. J. ; Heimans, J. J. ; Pinedo, H. M. / Suramin : Rapid loading and weekly maintenance regimens for cancer patients. In: Journal of Clinical Oncology. 1992 ; Vol. 10, No. 11. pp. 1788-1794.
@article{b07bf4abf28446779769409c904d0fd2,
title = "Suramin: Rapid loading and weekly maintenance regimens for cancer patients",
abstract = "Purpose: Suramin is an anticancer agent with a narrow therapeutic window and a terminal half-life of 45 to 55 days. These characteristics make it necessary to control accurately the serum concentrations of the drug. Therefore, the aim of the present study was to develop a rapid loading regimen, followed by weekly administration of suramin to maintain serum concentrations of between 150 and 300 μg/mL for 8 weeks. Patients and Methods: Eligible patients were treated with five different loading regimens. Initially, weekly maintenance doses were estimated manually by the treating physician. Subsequently, computer-assisted dosing that used Bayesian pharmacokinetic modeling was used. Results: Thirty-eight courses of suramin that were administered to 35 patients were studied. The optimal loading regimen consisted of a continuous infusion of 600 mg/m2 during a 24-hour period, which resulted in a mean serum concentration of 319 μg/mL. Potentially toxic concentrations that were observed with shorter infusions were avoided. Maintenance treatment, which used the weekly administration of suramin during a 6-hour period, seemed to be able to maintain mean suramin serum trough concentrations of 150 μg/mL, while preventing mean peak concentrations of more than 300 μg/mL. The use of Bayesian pharmacokinetics was superior to manual estimation in tailoring the optimal dose to the therapeutic window. Conclusions: Continuous infusion is the optimal way of delivering suramin during the loading phase. To maintain trough levels and peak levels within a narrower therapeutic window, suramin will have to be administered more frequently than once a week. Bayesian modeling based on individual serum levels and population pharmacokinetics allows accurate dosing to maintain suramin levels within the therapeutic window.",
author = "{Van Rijswijk}, {R. E N} and {Van Loenen}, {A. C.} and J. Wagstaff and E. Meijer and R. Lopez and {Van Groeningen}, {C. J.} and Heimans, {J. J.} and Pinedo, {H. M.}",
year = "1992",
language = "English (US)",
volume = "10",
pages = "1788--1794",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Suramin

T2 - Rapid loading and weekly maintenance regimens for cancer patients

AU - Van Rijswijk, R. E N

AU - Van Loenen, A. C.

AU - Wagstaff, J.

AU - Meijer, E.

AU - Lopez, R.

AU - Van Groeningen, C. J.

AU - Heimans, J. J.

AU - Pinedo, H. M.

PY - 1992

Y1 - 1992

N2 - Purpose: Suramin is an anticancer agent with a narrow therapeutic window and a terminal half-life of 45 to 55 days. These characteristics make it necessary to control accurately the serum concentrations of the drug. Therefore, the aim of the present study was to develop a rapid loading regimen, followed by weekly administration of suramin to maintain serum concentrations of between 150 and 300 μg/mL for 8 weeks. Patients and Methods: Eligible patients were treated with five different loading regimens. Initially, weekly maintenance doses were estimated manually by the treating physician. Subsequently, computer-assisted dosing that used Bayesian pharmacokinetic modeling was used. Results: Thirty-eight courses of suramin that were administered to 35 patients were studied. The optimal loading regimen consisted of a continuous infusion of 600 mg/m2 during a 24-hour period, which resulted in a mean serum concentration of 319 μg/mL. Potentially toxic concentrations that were observed with shorter infusions were avoided. Maintenance treatment, which used the weekly administration of suramin during a 6-hour period, seemed to be able to maintain mean suramin serum trough concentrations of 150 μg/mL, while preventing mean peak concentrations of more than 300 μg/mL. The use of Bayesian pharmacokinetics was superior to manual estimation in tailoring the optimal dose to the therapeutic window. Conclusions: Continuous infusion is the optimal way of delivering suramin during the loading phase. To maintain trough levels and peak levels within a narrower therapeutic window, suramin will have to be administered more frequently than once a week. Bayesian modeling based on individual serum levels and population pharmacokinetics allows accurate dosing to maintain suramin levels within the therapeutic window.

AB - Purpose: Suramin is an anticancer agent with a narrow therapeutic window and a terminal half-life of 45 to 55 days. These characteristics make it necessary to control accurately the serum concentrations of the drug. Therefore, the aim of the present study was to develop a rapid loading regimen, followed by weekly administration of suramin to maintain serum concentrations of between 150 and 300 μg/mL for 8 weeks. Patients and Methods: Eligible patients were treated with five different loading regimens. Initially, weekly maintenance doses were estimated manually by the treating physician. Subsequently, computer-assisted dosing that used Bayesian pharmacokinetic modeling was used. Results: Thirty-eight courses of suramin that were administered to 35 patients were studied. The optimal loading regimen consisted of a continuous infusion of 600 mg/m2 during a 24-hour period, which resulted in a mean serum concentration of 319 μg/mL. Potentially toxic concentrations that were observed with shorter infusions were avoided. Maintenance treatment, which used the weekly administration of suramin during a 6-hour period, seemed to be able to maintain mean suramin serum trough concentrations of 150 μg/mL, while preventing mean peak concentrations of more than 300 μg/mL. The use of Bayesian pharmacokinetics was superior to manual estimation in tailoring the optimal dose to the therapeutic window. Conclusions: Continuous infusion is the optimal way of delivering suramin during the loading phase. To maintain trough levels and peak levels within a narrower therapeutic window, suramin will have to be administered more frequently than once a week. Bayesian modeling based on individual serum levels and population pharmacokinetics allows accurate dosing to maintain suramin levels within the therapeutic window.

UR - http://www.scopus.com/inward/record.url?scp=0027057485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027057485&partnerID=8YFLogxK

M3 - Article

C2 - 1403059

AN - SCOPUS:0027057485

VL - 10

SP - 1788

EP - 1794

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -